Sartor O - Search Results

1

Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer.

Moses M, Niu A, Lilly MB, Hahn AW, Nussenzveig R, Ledet E, Manogue C, Cotogno P, Lewis B, Layton J, Agarwal N, Sartor O, Barata PC. Moses M, et al. Among authors: sartor o. Cancer Treat Res Commun. 2020;24:100193. doi: 10.1016/j.ctarc.2020.100193. Epub 2020 Jul 14. Cancer Treat Res Commun. 2020. PMID: 32702615 Free article.

2

A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone-refractory prostate cancer.

Figg WD, Thibault A, Cooper MR, Reid R, Headlee D, Dawson N, Kohler DR, Reed E, Sartor O. Figg WD, et al. Among authors: sartor o. Cancer. 1995 Apr 15;75(8):2159-64. doi: 10.1002/1097-0142(19950415)75:8<2159::aid-cncr2820750820>3.0.co;2-o. Cancer. 1995. PMID: 7535186 Clinical Trial.

3

Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables.

Dawson NA, Cooper MR, Figg WD, Headlee DJ, Thibault A, Bergan RC, Steinberg SM, Sausville EA, Myers CE, Sartor O. Dawson NA, et al. Among authors: sartor o. Cancer. 1995 Aug 1;76(3):453-62. doi: 10.1002/1097-0142(19950801)76:3<453::aid-cncr2820760316>3.0.co;2-e. Cancer. 1995. PMID: 8625127 Clinical Trial.

4

Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy.

Choueiri TK, Xie W, D'Amico AV, Ross RW, Hu JC, Pomerantz M, Regan MM, Taplin ME, Kantoff PW, Sartor O, Oh WK. Choueiri TK, et al. Among authors: sartor o. Cancer. 2009 Mar 1;115(5):981-7. doi: 10.1002/cncr.24064. Cancer. 2009. PMID: 19152438 Free PMC article.

5

Cabazitaxel for the treatment of castration-resistant prostate cancer.

Agarwal N, Sonpavde G, Sartor O. Agarwal N, et al. Among authors: sartor o. Future Oncol. 2011 Jan;7(1):15-24. doi: 10.2217/fon.10.168. Future Oncol. 2011. PMID: 21174534

6

Improving outcomes with recent advances in chemotherapy for castrate-resistant prostate cancer.

Sartor O, Halstead M, Katz L. Sartor O, et al. Clin Genitourin Cancer. 2010 Dec 1;8(1):23-8. doi: 10.3816/CGC.2010.n.004. Clin Genitourin Cancer. 2010. PMID: 21208852 Review.

7

Overcoming chemotherapy resistance in prostate cancer.

Madan RA, Pal SK, Sartor O, Dahut WL. Madan RA, et al. Among authors: sartor o. Clin Cancer Res. 2011 Jun 15;17(12):3892-902. doi: 10.1158/1078-0432.CCR-10-2654. Clin Cancer Res. 2011. PMID: 21680545 Free PMC article.

8

Combination therapy: Abiraterone prolongs survival in metastatic prostate cancer.

Sartor O. Sartor O. Nat Rev Clin Oncol. 2011 Aug 2;8(9):515-6. doi: 10.1038/nrclinonc.2011.111. Nat Rev Clin Oncol. 2011. PMID: 21808270

9

Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting.

Sartor O, Michels RM, Massard C, de Bono JS. Sartor O, et al. Oncologist. 2011;16(11):1487-97. doi: 10.1634/theoncologist.2010-0412. Epub 2011 Nov 2. Oncologist. 2011. PMID: 22048000 Free PMC article. Review.

10

The relationship between symptomatology and treatment selection in metastatic castrate-resistant prostate cancer.

Small EJ, Penson DF, Sartor O. Small EJ, et al. Among authors: sartor o. Clin Adv Hematol Oncol. 2011 Jul;9(7 Suppl 13):1-15. Clin Adv Hematol Oncol. 2011. PMID: 22361784 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

525 results

Search Page

Filters